Brand Institute, announced its successful partnership with Arvinas, Inc. on the development of the nonproprietary name bavdegalutamide. Bavdegalutamide, also referred to as ARV-110, was published as a recommended INN in April of 2022. The product was granted fast-track designation by the FDA in May of 2019 for the treatment of metastatic castration-resistant prostate cancer.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
25.22 USD | -0.32% | -1.75% | -38.73% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.73% | 1.73B | |
+15.19% | 121B | |
+19.91% | 114B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B | |
+119.39% | 10.96B |
- Stock Market
- Equities
- ARVN Stock
- News Arvinas, Inc.
- Brand Institute Partners on Nonproprietary Name for Novel Protein Degrader Under Development by Arvinas, Inc